Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Novavax Inc (NVAX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Novavax Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Novavax Inc trades at $9.27 (market cap $1.53B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 26.1× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | NVAX | |
|---|---|---|
Market Cap | $39.89B | $1.53B |
Sector | Health | Health |
52-Week High | $491.22 | $11.19 |
52-Week Low | $278.09 | $6.22 |
Enterprise Value | $38.15B | $1.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Novavax (NVAX) trades at $9.33, down 0.74% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $14.00. The company reported revenue of $1.12 billion in 2025, swinging to a net income of $440.30 million, but faces negative cash flow and a negative shareholder equity position. Recent news highlights shareholder dissent at the AGM and investor attention amid vaccine stock volatility.
The outlook is mixed: strong valuation ratios and recent earnings beats suggest upside potential, but persistent cash burn and competitive pressures in the vaccine market pose significant risks. Analyst sentiment is predominantly bullish, yet the stock's performance remains sensitive to clinical developments and market sentiment toward biotech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
